Salamon Tiberiu MD is categorized under Internal Medicine Practitioners in New York City, NY and active since 1978.
Salamon Tiberiu MD was established in 1978, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Internal Medicine Practitioners business, which does work in the B2C market, and is classified as a Internal Medicine Practitioners, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Tiberiu Salamon at the company’s single location by writing to 225 East 79th St Floor 1, New York City, New York NY 10075 or by phoning (212) 737-3586. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Salamon Tiberiu MD |
| Contact Person: | Tiberiu Salamon |
| Address: | 225 East 79th St Floor 1, New York City, New York 10075 |
| Phone Number: | (212) 737-3586 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1978 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Practitioners |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Salamon Tiberiu MD was started in 1978 to provide professional Internal Medicine Practitioners under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Tiberiu Salamon for inquiries that concern Salamon Tiberiu MD by calling the company number (212) 737-3586, as your correspondence is most welcome. Additionally, the physical location of the single location of Salamon Tiberiu MD can be found at the coordinates 40.774055,-73.956725 as well as the street address 225 East 79th St Floor 1 in New York City, New York 10075.
For its online presence, you may visit Salamon Tiberiu MD’s website at and engage with its social media outlets through on Twitter and on Facebook.